DC-CIK细胞免疫治疗恶性肿瘤的临床研究  

Treatment of malignant tumor patients by DC-CIK cells

作　　者：王娟[1] 陶贞霞[1] 刘荣英[1] 曹艳丽[1] 许卫星[1] 李静[1] 沈杰[1] 王庆[1] 王瑞环[1] 赵芳[1] 刘春燕[1] 张睿[1] 张敏娟[1] 马洪玉[1] 苏国宏[1] 

机构地区：[1]河北省沧州市中心医院血液科

出　　处：《免疫学杂志》2009年第1期71-74,共4页Immunological Journal

基　　金：河北省医学适用跟踪项目资助(2005)

摘　　要：目的探讨树突状细胞(DC)-细胞因子诱导的杀伤细胞(CIK)细胞免疫治疗恶性肿瘤的疗效及机制。方法采集13例恶性肿瘤患者外周血单个核细胞,贴壁细胞经IL-4、GM-CSF、TNF-a诱导,并经流式细胞仪检测证实为DC,悬浮细胞经CD3单抗、γ-干扰素、IL-2诱导,并经流式细胞仪检测证实为CIK细胞。DC分次淋巴引流区皮下注射,CIK细胞静脉输注。结果除1例肝癌骨转移患者经治疗无效死亡外,其余患者的临床症状、影像学均提示病变较前好转。结论DC-CIK细胞免疫治疗恶性肿瘤有确切疗效,延长患者生存期,提高生活质量。Objective To assess the therapeutic efficacy and the mechanism of DC-CIK immunotherapy against malignant tumors.Methods Peripheral blood mononuclear cells were isolated from 13 patients with malignant tumors.The attached cells were induced by TL-4,GM-CSF,and TNF-a,and then confirmed as DCs by flow cytometry;the suspension cells were induced by CD3 monoclonal antibody,γ-INF,and IL-2,and then confirmed as CIK cells by flow cytometry.Then DCs were injected in drain lymph node hypodermically,while CIK cells wer...

关 键 词：恶性肿瘤 树突状细胞 细胞因子诱导的杀伤细胞 细胞免疫治疗 

分 类 号：R730.5[医药卫生—肿瘤]